HealthCare Global Enterprises Limited (the Company) has entered into a Share Purchase Agreement (SPA) dated May 19, 2026, with BACC Health Care Private Limited (BACC) and Inviga Healthcare Fund I (Buyer) in relation to the divestment by way of sale of the Company s entire equity shareholding in BACC to the Buyer and its nominee, for a consideration of INR 37,64,44,788 (Indian Rupees Thirty Seven Crores Sixty Four Lakhs Forty Four Thousand Seven Hundred and Eighty Eight Only), on the terms agreed under the SPA. BACC is not a material subsidiary of the Company and is engaged in the business of fertility and reproductive healthcare services, which is not a core business activity of the Company. The said transaction has been approved by the Board and Audit Committee pursuant to the meetings held on May 19, 2026, as disclosed by our intimation dated May 19, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HCG has entered into a Share Purchase Agreement to sell its entire stake in BACC Health Care Private Limited to Inviga Healthcare Fund I for INR 37.64 crores. BACC operates in fertility and reproductive healthcare services, which is explicitly stated as non-core to HCG's business. The transaction is classified as a related party transaction since Inviga Healthcare Fund I is controlled by Dr. B.S. Ajaikumar, HCG's Promoter and Non-Executive Chairman. However, HCG states the deal is at arm's length with independent valuation and competitive process followed. BACC contributed only 4.45% to HCG's standalone revenue and 1.09% to net worth in FY 2025-26, making it a small, non-material divestment. The deal is expected to close within 4-5 weeks, with INR 28.23 crores at closing and INR 9.41 crores deferred over 18 months.
This is a minor portfolio pruning exercise for HCG, divesting a small, non-core fertility business to a promoter-linked fund. The impact on HCG's financials will be negligible given BACC's minimal contribution, but it may attract regulatory scrutiny due to the related party nature of the transaction.